Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia

Author(s): Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, et al.

Abstract

Aims/hypothesis: Recent evidence suggests that a particular gut microbial community may favour occurrence of the metabolic diseases. Recently, we reported that high-fat (HF) feeding was associated with higher endotoxaemia and lower Bifidobacterium species (spp.) caecal content in mice. We therefore tested whether restoration of the quantity of caecal Bifidobacterium spp. could modulate metabolic endotoxaemia, the inflammatory tone and the development of diabetes.

Methods: Since bifidobacteria have been reported to reduce intestinal endotoxin levels and improve mucosal barrier function, we specifically increased the gut bifidobacterial content of HF-diet-fed mice through the use of a prebiotic (oligofructose [OFS]).

Results: Compared with normal chow-fed control mice, HF feeding significantly reduced intestinal Gram-negative and Gram-positive bacteria including levels of bifidobacteria, a dominant member of the intestinal microbiota, which is seen as physiologically positive. As expected, HF-OFS-fed mice had totally restored quantities of bifidobacteria. HF-feeding significantly increased endotoxaemia, which was normalised to control levels in HF-OFS-treated mice. Multiple-correlation analyses showed that endotoxaemia significantly and negatively correlated with Bifidobacterium spp., but no relationship was seen between endotoxaemia and any other bacterial group. Finally, in HF-OFS-treated-mice, Bifidobacterium spp. significantly and positively correlated with improved glucose tolerance, glucose-induced insulin secretion and normalised inflammatory tone (decreased endotoxaemia, plasma and adipose tissue proinflammatory cytokines).

Conclusions/interpretation: Together, these findings suggest that the gut microbiota contribute towards the pathophysiological regulation of endotoxaemia and set the tone of inflammation for occurrence of diabetes and/or obesity. Thus, it would be useful to develop specific strategies for modifying gut microbiota in favour of bifidobacteria to prevent the deleterious effect of HF-diet-induced metabolic diseases.

Similar Articles

Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review

Author(s): Arab JP, Candia R, Zapata R, Muñoz C, Arancibia JP, et al.

Gut microbiota and non-alcoholic fatty liver disease: new insights

Author(s): Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

Author(s): Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, et al.

Increased oxidative stress in obesity and its impact on metabolic syndrome

Author(s): Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, et al.

Role of gut microbiota: obesity and NAFLD

Author(s): Gangarapu V, Yıldız K, Ince AT, Baysal B

Hepatic histology in obese patients undergoing bariatric surgery

Author(s): Machado M, Marques-Vidal P, Cortez-Pinto H

Gut microbiota and liver disease

Author(s): Goel A, Gupta M, Aggarwal R

An obesity-associated gut microbiome with increased capacity for energy harvest

Author(s): Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, et al.

Obesity alters gut microbial ecology

Author(s): Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, et al.

Microbial ecology: human gut microbes associated with obesity

Author(s): Ley RE, Turnbaugh PJ, Klein S, Gordon JI

Microbiota and SCFA in lean and overweight healthy subjects

Author(s): Schwiertz A, Taras D, Schäfer K, Beijer S, Bos NA, et al.

Human colonic microbiota associated with diet, obesity and weight loss

Author(s): Duncan SH, Lobley GE, Holtrop G, Ince J, Johnstone AM, et al.

Enterotypes of the human gut microbiome

Author(s): Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, et al.

The gut microbiota as an environmental factor that regulates fat storage

Author(s): Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, et al.

Mechanisms underlying the resistance to diet-induced obesity in germ-free mice

Author(s): Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI

Human gut microbiota in obesity and after gastric bypass

Author(s): Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, et al.

The gut microbiota, obesity and insulin resistance

Author(s): Shen J, Obin MS, Zhao L

Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice

Author(s): Caricilli AM, Picardi PK, de Abreu LL, Ueno M, Prada PO, et al.

The role of gut microbiota on insulin resistance

Author(s): Caricilli AM, Saad MJ

Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance

Author(s): Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, et al.

NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance

Author(s): Tamrakar AK, Schertzer JD, Chiu TT, Foley KP, Bilan PJ, et al.

Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis

Author(s): Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, et al.

Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice

Author(s): Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, et al.

Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis

Author(s): Rivera CA, Gaskin L, Allman M, Pang J, Brady K, et al.

Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5

Author(s): Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, et al.

NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis

Author(s): Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, et al.

A functional role for Nlrp6 in intestinal inflammation and tumorigenesis

Author(s): Chen GY, Liu M, Wang F, Bertin J, Núñez G

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

Author(s): Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, et al.

NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion

Author(s): Wlodarska M, Thaiss CA2, Nowarski R3, Henao-Mejia J3, Zhang JP4, et al.

NLRP6 negatively regulates innate immunity and host defence against bacterial pathogens

Author(s): Anand PK, Malireddi RK, Lukens JR, Vogel P, Bertin J, et al.

Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin

Author(s): Bergheim I, Weber S, Vos M, Krämer S, Volynets V, et al.

Dietary modulation of the human colonic microbiota: updating the concept of prebiotics

Author(s): Gibson GR, Probert HM, Loo JV, Rastall RA, Roberfroid MB

Review article: prebiotics in the gastrointestinal tract

Author(s): Macfarlane S, Macfarlane GT, Cummings JH

Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis

Author(s): Ma YY, Li L, Yu CH, Shen Z, Chen LH, et al.